Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diosmectite is a natural silicate of aluminium and magnesium classified as an intestinal adsorbent. It is primarily used for the treatment of acute and chronic diarrhoea (both infectious and non-infectious), including irritable bowel syndrome with diarrhea, as well as diarrhea associated with chemotherapy, radiation therapy, or HIV/AIDS[1][2][3]. Diosmectite acts locally in the gastrointestinal tract without systemic absorption. Its mechanism of action involves several effects: - Adsorption of bacteria, viruses, bacterial enterotoxins, and other toxins in the gut lumen. - Strengthening and protecting the intestinal mucus barrier by binding to mucins and increasing colonic mucin levels. - Reducing inflammation through modulation of proinflammatory cytokines. - Inhibiting viral replication (notably rotavirus) and reducing oxidative stress in enterocytes[2][6]. These actions help restore stool consistency and reduce diarrheal symptoms. Diosmectite is usually administered orally as a suspension in water.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diosmectite.